SCHEMBL19360803

SCHEMBL19360803

O=C(Oc1c(F)c(F)cc(F)c1F)c1ccc(I)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.35
▸ MAOB P27338 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ SLC2A1 P11166 1/20 0.34
▸ SLC2A4 P14672 1/20 0.34
▸ MAPT P10636 3/20 0.33
▸ VNN1 O95497 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ TTR P02766 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29525674 0.85 KCNQ3 (0.41) MAPK1KMT2AMEN1NPC1RAB9A
SCHEMBL416586 0.85 KCNQ3 (0.41) MAPK1KMT2AMEN1NPC1RAB9A
SCHEMBL6726735 0.85 KCNQ3 (0.41) MAPK1KMT2AMEN1NPC1RAB9A
SCHEMBL19816909 0.84 MAPK1 (0.53) MAPK1KMT2AMEN1NPC1RAB9A
SCHEMBL6726742 0.84 KMT2A (0.50) MAPK1KMT2AMEN1KDM4EL3MBTL1
SCHEMBL29815064 0.82 NAPRT (0.47) NPC1RAB9AL3MBTL1MAPTLMNA
SCHEMBL10001386 0.82 NAPRT (0.47) NPC1RAB9AL3MBTL1MAPTLMNA
SCHEMBL17544977 0.81 ALOX5AP (0.41) MAPK1KDM4EL3MBTL1HDAC6MAOB
SCHEMBL23812490 0.80 ALDH1A1 (0.37) MAPK1KMT2AMEN1NPC1RAB9A
SCHEMBL10001384 0.80 MAPK1 (0.36) MAPK1KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117714-A1 IMAGING METHODS AND RADIOTRACERS FOR USE THEREIN VESTLANDETS INNOVASJONS SELSKAP AS (VIS) (NO) 2022-06-09 — — WO disclosed
US-20170267717-A1 Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267717-A1 Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer FGB, F13B, FAP MAPK1 4019/4885KMT2A 2206/4885MEN1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback